The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Targeting WEE1 Kinase in Cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
Cell-cycle checkpoints and cancer
Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836
Universal control mechanism regulating onset of M-phase
Nurse, P. (1990) · Nature · doi:10.1038/344503a0 · Cited by 2,831
ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks
Jazayeri, A., Falck, J., Lukas, C., Bartek, J., Smith, G. C. M., Lukas, J., & Jackson, S. P. (2006) · Nature Cell Biology · doi:10.1038/ncb1337 · Cited by 1,064
FDA-approved small-molecule kinase inhibitors
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.005 · Cited by 1,013
Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro
Matsuoka, S., Rotman, G., Ogawa, A., Shiloh, Y., Tamai, K., & Elledge, S. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190030497 · Cited by 829
CDC25 phosphatases in cancer cells: key players? Good targets?
Boutros, R., Lobjois, V., & Ducommun, B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2169 · Cited by 714
The decision to enter mitosis: feedback and redundancy in the mitotic entry network
Lindqvist, A., Rodríguez-Bravo, V., & Medema, R. H. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200812045 · Cited by 565
Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0463 · Cited by 540
BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage
Yarden, R. I., Pardo-Reoyo, S., Sgagias, M., Cowan, K. H., & Brody, L. C. (2002) · Nature Genetics · doi:10.1038/ng837 · Cited by 484
Heald, R., McLoughlin, M., & McKeon, F. (1993) · Cell · doi:10.1016/0092-8674(93)80048-j · Cited by 462
G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer
Bucher, N., & Britten, C. D. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604208 · Cited by 349
Do, K., Wilsker, D., Ji, J., Zlott, J., Freshwater, T., Kinders, R. J., Collins, J., Chen, A. P., Doroshow, J. H., & Kummar, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4009 · Cited by 322
Human Myt1 Is a Cell Cycle-regulated Kinase That Inhibits Cdc2 but Not Cdk2 Activity
Booher, R. N., Holman, P. S., & Fattaey, A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.35.22300 · Cited by 313
Metz, J. T., Johnson, E. F., Soni, N. B., Merta, P. J., Kifle, L., & Hajduk, P. J. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.530 · Cited by 311
Mir, S. E., De Witt Hamer, P. C., Krawczyk, P. M., Balaj, L., Claes, A., Niers, J. M., Van Tilborg, A. A. G., Zwinderman, A. H., Geerts, D., Kaspers, G. J. L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.011 · Cited by 294
G. Dunphy, W. (1994) · Trends in Cell Biology · doi:10.1016/0962-8924(94)90142-2 · Cited by 276
Rajeshkumar, N. V., De Oliveira, E., Ottenhof, N., Watters, J., Brooks, D., Demuth, T., Shumway, S. D., Mizuarai, S., Hirai, H., Maitra, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2580 · Cited by 274
Wee1 kinase as a target for cancer therapy
Do, K., Doroshow, J. H., & Kummar, S. (2013) · Cell Cycle · doi:10.4161/cc.26062 · Cited by 273
WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe
De Witt Hamer, P. C., Mir, S. E., Noske, D., Van Noorden, C. J. F., & Würdinger, T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2537 · Cited by 249
Hirai, H., Arai, T., Okada, M., Nishibata, T., Kobayashi, M., Sakai, N., Imagaki, K., Ohtani, J., Sakai, T., Yoshizumi, T., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.7.11115 · Cited by 237
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
Wang, Y., Li, J., Booher, R. N., Kraker, A. J., Lawrence, T. S., Leopold, W. R., & Sun, Y. (2001) · PubMed · Cited by 210
Cyclins and Cyclin–Dependent Kinases: Comparative Study of Hepatocellular Carcinoma Versus Cirrhosis
Masaki, T., Shiratori, Y., Rengifo, W., Igarashi, K., Yamagata, M., Kurokohchi, K., Uchida, N., Miyauchi, Y., Yoshiji, H., Watanabe, S., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50112 · Cited by 207
Measuring and interpreting the selectivity of protein kinase inhibitors
Smyth, L. A., & Collins, I. (2009) · Journal of Chemical Biology · doi:10.1007/s12154-009-0023-9 · Cited by 197
Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease
Domínguez-Kelly, R., Martín, Y., Koundrioukoff, S., Tanenbaum, M. E., Smits, V. A. J., Medema, R. H., Debatisse, M., & Freire, R. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201101047 · Cited by 196
Triggering the all-or-nothing switch into mitosis
O'Farrell, P. H. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02142-0 · Cited by 196
Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy
Guertin, A. D., Li, J., Liu, Y., Hurd, M. S., Schuller, A. G., Long, B., Hirsch, H. A., Feldman, I., Benita, Y., Toniatti, C., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0025 · Cited by 172
Wee1-dependent mechanisms required for coordination of cell growth and cell division
Kellogg, D. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00908 · Cited by 168
Targeting the S and G2 checkpoint to treat cancer
Chen, T., Stephens, P. A., Middleton, F. K., & Curtin, N. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.009 · Cited by 166
Magnussen, G. I., Holm, R., Emilsen, E., Rosnes, A. K. R., Slipicevic, A., & Flørenes, V. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038254 · Cited by 144
The clinical significance of Cyclin B1 and Wee1 expression innon-small-cell lung cancer
Yoshida, T., Tanaka, S., Mogi, A., Shitara, Y., & Kuwano, H. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh073 · Cited by 144
Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA Damage
Johnson, N., Cai, D. D., Kennedy, R. D., Pathania, S., Arora, M., Li, Y.-C., D’Andrea, A. D., Parvin, J. D., & Shapiro, G. I. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.06.036 · Cited by 142
Knockdown of Chk1, Wee1 and Myt1 by RNA Interference Abrogates G2 Checkpoint and Induces Apoptosis
Wang, Y., Decker, S. J., & Sebolt, J. S. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.3.697 · Cited by 138
Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets
Iorns, E. J., Lord, C. J., Grigoriadis, A. E., McDonald, S., Fenwick, K., Mackay, A. G., Mein, C. A., Natrajan, R., Savage, K., Tamber, N., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005120 · Cited by 132
Linden, A. A. V., Baturin, D., Ford, J. B., Fosmire, S. P., Gardner, L. A., Korch, C. T., Reigan, P., & Porter, C. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0424 · Cited by 130
Self-citationMK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells
Kreahling, J. M., Gemmer, J. Y., Reed, D. R., Letson, D. G., Bui, M. M., & Altiok, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0529 · Cited by 125
Targeting Wee1 for the treatment of pediatric high-grade gliomas
Mueller, S., Hashizume, R., Yang, X., Kolkowitz, I., Olow, A., Phillips, J. J., Smirnov, I. V., Tom, M. W., Prados, M. D., James, C. D., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not220 · Cited by 124
Palmer, B. D., Thompson, A. M., Booth, R. J., Dobrusin, E. M., Kraker, A. J., Lee, H. H., Lunney, E. A., Mitchell, L. H., Ortwine, D. F., Smaill, J. B., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0512591 · Cited by 112
Leijen, S., Beijnen, J. H., & Schellens, J. H. M. (2010) · Current Clinical Pharmacology · doi:10.2174/157488410791498824 · Cited by 112
Lal, S., Burkhart, R. A., Beeharry, N., Bhattacharjee, V., Londin, E. R., Cozzitorto, J. A., Romeo, C., Jimbo, M., Norris, Z. A., Yeo, C. J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1915 · Cited by 110
Sarcar, B., Kahali, S., Prabhu, A. H., Shumway, S. D., Xu, Y., Demuth, T., & Chinnaiyan, P. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0469 · Cited by 110
Structure and Inhibition of the Human Cell Cycle Checkpoint Kinase, Wee1A Kinase
Squire, C. J., Dickson, J. M. J. J., Ivanović, I., & Baker, E. N. (2005) · Structure · doi:10.1016/j.str.2004.12.017 · Cited by 105
Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array
Backert, S., Gelos, M., Kobalz, U., Hanski, M., B�hm, C., Mann, B., L�vin, N., Gratchev, A. N., Mannsmann, U., Moyer, M. P., et al. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990909)82:6<868::aid-ijc16>3.0.co;2-w · Cited by 105
H2B Tyr37 phosphorylation suppresses expression of replication-dependent core histone genes
Mahajan, K. N., Fang, B., Koomen, J. M., & Mahajan, N. P. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2356 · Cited by 99
Panek, R. L., Lu, G. H., Klutchko, S. R., Batley, B. L., Dahring, T. K., Hamby, J. M., Hallak, H., Doherty, A. M., & Keiser, J. A. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37140-x · Cited by 96
Recent Advances in the Development of Multi-Kinase Inhibitors
Krug, M., & Hilgeroth, A. (2008) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955708786369591 · Cited by 95
Pokorny, J. L., Calligaris, D., Gupta, S. K., Iyekegbe, D. O., Mueller, D. J., Bakken, K. K., Carlson, B. L., Schroeder, M. A., Evans, D. L., Lou, Z., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2588 · Cited by 95
Kreahling, J. M., Foroutan, P., Reed, D. R., Martinez, G. V., Razabdouski, T. N., Bui, M. M., Raghavan, M., Letson, D. G., Gillies, R. J., & Altiok, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057523 · Cited by 93
Murrow, L. M., Garimella, S. V., Jones, T. L., Caplen, N. J., & Lipkowitz, S. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0571-2 · Cited by 92
Porter, C. C., Kim, J.-S., Fosmire, S. P., Gearheart, C. M., van Linden, A., Baturin, D., Zaberezhnyy, V., Patel, P. R., Gao, D., Tan, A. C., et al. (2012) · Leukemia · doi:10.1038/leu.2011.392 · Cited by 88
RNAi screening of the kinome with cytarabine in leukemias
Tibes, R., Bogenberger, J. M., Chaudhuri, L., Hagelstrom, R. T., Chow, D. C., Buechel, M. E., Gonzales, I. M., Demuth, T., Slack, J. L., Mesa, R. A., et al. (2012) · Blood · doi:10.1182/blood-2011-07-367557 · Cited by 85
Slipicevic, A., Holth, A., Hellesylt, E., Trope, C. G., Davidson, B., & Flørenes, V. A. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.07.102 · Cited by 81
Lian, G., Lu, J., Hu, J., Zhang, J., Cross, S. H., Ferland, R. J., & Sheen, V. L. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0894-12.2012 · Cited by 79
WEE1 Kinase Inhibition Enhances the Radiation Response of Diffuse Intrinsic Pontine Gliomas
Caretti, V., Hiddingh, L., Lagerweij, T., Schellen, P., Koken, P. W., Hulleman, E., van Vuurden, D. G., Vandertop, W. P., Kaspers, G. J. L., Noske, D. P., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0735 · Cited by 78
Hashimoto, O., Shinkawa, M., Torimura, T., Nakamura, T., Selvendiran, K., Sakamoto, M., Koga, H., Ueno, T., & Sata, M. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-292 · Cited by 75
Harris, P. S., Venkataraman, S., Alimova, I. N., Birks, D. K., Balakrishnan, I., Cristiano, B., Donson, A. M., Dubuc, A. M., Taylor, M. D., Foreman, N. K., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-72 · Cited by 71
Self-citationExpression and prognostic value of the WEE1 kinase in gliomas
Music, D., Dahlrot, R. H., Hermansen, S. K., Hjelmborg, J., de Stricker, K., Hansen, S., & Kristensen, B. W. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-2050-4 · Cited by 71
Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement
af Hällström, T., Jäämaa, S., Mönkkönen, M., Peltonen, K., Andersson, L. C., Medema, R. H., Peehl, D. M., & Laiho, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609299104 · Cited by 68
Matheson, C. J., Venkataraman, S., Amani, V. M., Harris, P. S., Backos, D. S., Donson, A. M., Wempe, M. F., Foreman, N. K., Vibhakar, R., & Reigan, P. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00725 · Cited by 64
Self-citationRNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells
Arora, S., Bisanz, K. M., Peralta, L. A., Basu, G. D., Choudhary, A. K., Tibes, R., & Azorsa, D. O. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.05.006 · Cited by 60
Li, J., Wang, Y., Sun, Y., & Lawrence, T. S. (2002) · Radiation Research · doi:10.1667/0033-7587(2002)157[0322:wttigp]2.0.co;2 · Cited by 55
High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients
Magnussen, G. I., Hellesylt, E., Nesland, J. M., Trope, C. G., Flørenes, V. A., & Holm, R. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-288 · Cited by 45
Inhibition of proteasome‐dependent degradation of Wee1 in G 2 ‐arrested Hep3B cells by TGFβ1
Hashimoto, O., Ueno, T., Kimura, R., Ohtsubo, M., Nakamura, T., Koga, H., Torimura, T., Uchida, S., Yamashita, K., & Sata, M. (2003) · Molecular Carcinogenesis · doi:10.1002/mc.10111 · Cited by 45
Lescarbeau, R. S., Lei, L., Bakken, K. K., Sims, P. A., Sarkaria, J. N., Canoll, P., & White, F. M. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0692 · Cited by 38
Leijen, S., Schellens, J. H. M., Shapiro, G. I., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3067 · Cited by 35
Schellens, J. H. M., Shapiro, G. I., Pavlick, A. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3068 · Cited by 15
Cited by
Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00404-3 · Cited by 1,506
Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma
Clark, D. J., Dhanasekaran, S. M., Petralia, F., Pan, J., Song, X., Hu, Y., da Veiga Leprevost, F., Reva, B., Lih, T.-S. M., Chang, H.-Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.007 · Cited by 730
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564601 · Cited by 719
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
Unravelling the biology of SCLC: implications for therapy
Sabari, J. K., Lok, B. H., Laird, J. H., Poirier, J. T., & Rudin, C. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.71 · Cited by 490
Metadata
- Authors
- Matheson, C. J., Backos, D. S., & Reigan, P.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 37
- Issue
- 10
- Pages
- 872-881
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2470708296
- Cited by
- 408
- References
- 66
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.